文献速递产科母胎医学生殖医学

孕妇血浆全基因组游离DNA可检测早期与复发性流产中的胎儿非整倍体并指导后续管理

Maternal plasma genome-wide cell-free DNA can detect fetal aneuploidy in early and recurrent pregnancy loss and can be used to direct further workup.
PubMed 文献 · Hum Reprod · 2020-01-01

这项前瞻性诊断试验纳入109例孕14周前流产患者,比较全基因组cfDNA与绒毛染色体核型分析。在86例可评估样本中,采用流产特异性阈值时cfDNA检测非整倍体的敏感性为82%、特异性为90%,可替代绒毛染色体分析并指导复发性流产的后续检查。

要点

  • 全基因组cfDNA检测可作为复发性流产患者绒毛染色体分析的替代方案。
  • 流产特异性阈值下cfDNA检测非整倍体敏感性82%、特异性90%。
  • 若cfDNA提示非整倍体可不再进一步检查,未检出异常则行推荐复发性流产检查。

核心结论

  • 全基因组cfDNA检测可替代复发性流产患者绒毛组织的染色体分析,并指导后续管理。

研究设计与样本

  • 2018年3月至2019年1月在一家三级学术医疗中心开展的前瞻性诊断试验,纳入109例孕14周前流产患者。
  • 最终分析纳入86例绒毛染色体非嵌合结果且cfDNA结果可用的患者。
  • 前50例样本作为训练集,通过类似ROC分析建立流产特异性对数似然比阈值。

主要发现

  • 86例中55例(64%)检出染色体异常。
  • 第1、2、3和≥4次流产患者的染色体异常率分别为61%、72%、73%和44%。
  • cfDNA胎儿分数中位数为5%。
  • 采用非invasive产前筛查标准阈值时,cfDNA检测非整倍体的敏感性为55%(30/55),特异性为100%(31/31)。
  • 采用流产特异性阈值时,敏感性为82%(45/55),特异性为90%(28/31),阳性似然比8.46,阴性似然比0.20。

关键数值与推荐

  • 采用流产特异性对数似然比阈值时,cfDNA检测非整倍体的敏感性为82%(45/55),特异性为90%(28/31)。
  • 阳性似然比为8.46,阴性似然比为0.20。
  • 胎儿性别在所有病例中均被正确判定。

临床怎么用

  • 若cfDNA显示非整倍体,则不再进行进一步检查;若未检出异常,则按推荐进行复发性流产检查。
  • cfDNA检测可作为绒毛染色体分析的替代方案,用于指导复发性流产管理。

局限性

  • cfDNA假阳性结果可能导致患者不接受应有的复发性流产检查。
  • 采用胎儿分数4%的截断值可提高特异性,但会排除超过四分之一的病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can maternal plasma cell-free DNA (cfDNA) detect chromosomal anomalies in early pregnancy loss (EPL) and recurrent pregnancy loss (RPL)? SUMMARY ANSWER: Genome-wide cfDNA testing can serve as an alternative to cytogenetic analysis in products of conception (POCs) in RPLs and can guide further management. WHAT IS KNOWN ALREADY: Random chromosomal anomalies are the single most common cause for EPL and RPL. Cytogenetic analysis in POCs may be used to direct management in RPL because the detection of random chromosomal anomalies can eliminate further unwarranted testing. STUDY DESIGN, SIZE, DURATION: This was a prospective diagnostic test study from March 2018 to January 2019 of 109 patients experiencing pregnancy loss before 14 weeks gestation at a tertiary-care academic medical center. PARTICIPANTS/MATERIALS, SETTING, METHODS: Blood samples were drawn for genome-wide cfDNA testing prior to chorionic villous sampling for cytogenetic analysis of POCs with both short-term cultures (STCs) and long-term cultures (LTCs). Final analysis included 86 patients with non-mosaic cytogenetic results in POCs and available cfDNA results. Aneuploidy detection rates by cfDNA testing and POC cytogenetic analysis were compared. The first 50 samples served as the Training Set to establish pregnancy loss-specific log-likelihood ratio (LLR) thresholds using receiver-operator characteristic (ROC)-like analyses. These were then used for the entire cohort. MAIN RESULTS AND THE ROLE OF CHANCE: Seventy-eight samples (71.5%) had results available from both STC and LTC; 12 samples (11%) had a result from STC only, and 7 samples (6.4%) had a result from LTC only. A chromosomal anomaly was detected in 55/86 (64%). The rates of chromosomal anomalies were 61, 72, 73 and 44% in patients undergoing their first, second, third and ≥4th pregnancy losses, respectively. The median cfDNA fetal fraction was 5%. With standard LLR thresholds used for noninvasive prenatal screening, the sensitivity of cfDNA in detecting aneuploidy was 55% (30/55) and with a specificity of 100% (31/31). Using pregnancy loss-specific LLR thresholds, the sensitivity of cfDNA in detecting aneuploidy was 82% (45/55), with a specificity of 90% (28/31). The positive and negative likelihood ratios were 8.46 and 0.20, respectively. Fetal sex was correctly assigned in all cases. LIMITATIONS, REASONS FOR CAUTION: Cases with a false-positive result by cfDNA analysis would not receive the indicated RPL workup. Specificity could be improved by using a fetal fraction (FF) cutoff of 4%, but this would result in exclusion of more than a quarter of cases. WIDER IMPLICATIONS OF THE FINDINGS: cfDNA-based testing can serve as an alternative to POC cytogenetic analysis and can guide further RPL management: if cfDNA demonstrates aneuploidy, no further action is taken and if no abnormality is detected, the recommended RPL workup is performed. STUDY FUNDING/COMPETING INTEREST(S): Cell-free DNA testing was funded by Illumina, Inc., San Diego, CA. Y.Y. is a member of Illumina's Clinical Expert Panel and has received travel grants. A.B. has received travel grants from Illumina. All authors have no competing interest to declare.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Yaron Y, Pauta M, Badenas C, et al. Maternal plasma genome-wide cell-free DNA can detect fetal aneuploidy in early and recurrent pregnancy loss and can be used to direct further workup. Hum Reprod. 2020. PMID: 32386059. doi:10.1093/humrep/deaa073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。